Skip to content

The efficacy and safety of sequential application of tranexamic acid after joint replacement surgery in reducing blood loss in patients with different fibrinolytic phenotypes: a prospective randomized controlled trial

The efficacy and safety of sequential application of tranexamic acid after joint replacement surgery in reducing blood loss in patients with different fibrinolytic phenotypes: a prospective randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073045
Enrollment
Unknown
Registered
2023-06-30
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty

Interventions

Group A (Fibrinolytic ShutDown, FSD, no postoperative TXA):No postoperative TXA
Group B (Non-Fibrinolytic ShutDown, NFSD, no postoperative TXA):No postoperative TXA
Group C (Fibrinolytic ShutDown, FSD, receiving postoperative TXA):1.5g TXA i.v. q12h from postoperative days 1 to 3
Group D (Non-Fibrinolytic ShutDown, NFSD, receiving postoperative TXA):1.5g TXA i.v. q12h from postoperative days 1 to 3

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age = 18 years old; 2.Patients who need arthroplasty in the Department of orthopedics of our hospital

Exclusion criteria

Exclusion criteria: 1. Complicated with serious cardiovascular and cerebrovascular diseases (myocardial infarction, cerebral infarction, etc.); 2. Have obvious bleeding tendency (such as active gastrointestinal bleeding, cerebral hemorrhage, etc.); 3. Complicated with systemic or local venous thromboembolism (such as deep venous thrombosis, pulmonary embolism, etc.); 4. Previously identified coagulation dysfunction; 5. Complicated with severe neuromuscular system diseases; 6. Allergy to tranexamic acid.

Design outcomes

Primary

MeasureTime frame
Blood loss;

Secondary

MeasureTime frame
Transfusion rate;Transfusion volume;Thromboelastogram(TEG);Routine coagulation parameters(PT?PTR?INR?PTA?APTT?TT);Routine fibrinolysis parameters(FDP?D-D);Incidence of venous thromboembolism (DVT, PE);Wound complications (exudation, hematoma, infection);

Countries

China

Contacts

Public ContactWei Huang

The First Affiliated Hospital of Chongqing Medical University

huangwei68@263.net+86 138 8338 3330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026